Ingenol mebutate field-directed treatment of UVB-damaged skin reduces lesion formation and removes mutant p53 patches.
MouseRadiationSKH1/hr hairless miceMaleTopical0.05% gelApplied to established UVB-photodamaged skin
Model: Chronic UVB irradiation producing photodamaged skin with mutant p53 keratinocyte patches and subsequent skin lesions
Topical 0.05% ingenol mebutate reduced emergent skin lesions by approximately 70% and mutant p53 keratinocyte patches by approximately 70% versus placebo, with transient epidermal cell death, inflammation and eschar that resolved over several weeks.
Extraction: extract · Supplied extraction confidence: 0.65. Machine-extracted fields require source verification.